NY-ESO-1b

DRACPC ID  DRACPC0104

Active Ingredients   NY-ESO-1b

Description  A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers.

Synonyms  NY-ESO-1b Peptide (p157-165); NY-ESO-1b Peptide Vaccine; NY-ESO-1b

Type  Biotech

Disease  Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  Not available

Molecular Weight  Not available

Active Sequence  SLLMWITQC

Sequence Length  9

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  Not available

DrugBank Accession Number  Not available

NCI Thesaurus Code  C68999  

UNII  Not available  

CAS  Not available



Drug approval


Drug indication
    Investigated for use/treatment in Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00066729 A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer Phase 1 Treatment
NCT00199836 A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1. Cancer; Neoplasm Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.